[1]
|
Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. (2005) Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
|
[2]
|
Gharib, H., Papini, E., Paschke, R., Duick, D.S., Valcavi, R., Hegedus, L., et al. (2010) American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Journal of Endocrinological Investigation, 33, 287-291. https://doi.org/10.1007/BF03346587
|
[3]
|
Akkas, B.E., Demirel, B.B. and Vural, G.U. (2014) Prognostic Factors Affecting Disease-Specific Survival in Patients with Recurrent and/or Metastatic Differentiated Thyroid Carcinoma Detected by Positron Emission Tomography/Computed Tomography. Thyroid, 24, 287-295. https://doi.org/10.1089/thy.2013.0195
|
[4]
|
Kitahara, C.M. and Sosa, J.A. (2016) The Changing Incidence of Thyroid Cancer. Nature Reviews Endocrinology, 12, 646-653. https://doi.org/10.1038/nrendo.2016.110
|
[5]
|
Cabanillas, M.E., McFadden, D.G. and Durante, C. (2016) Thyroid Cancer. Lancet, 388, 2783-2795.
https://doi.org/10.1016/S0140-6736(16)30172-6
|
[6]
|
Fagin, J.A. and Wells Jr., S.A. (2016) Biologic and Clinical Perspectives on Thyroid Cancer. The New England Journal of Medicine, 375, 1054-1067. https://doi.org/10.1056/NEJMra1501993
|
[7]
|
Regalbuto, C., Frasca, F., Pellegriti, G., Malandrino, P., Marturano, I., Di Carlo, I., et al. (2012) Update on Thyroid Cancer Treatment. Future Oncology, 8, 1331-1348. https://doi.org/10.2217/fon.12.123
|
[8]
|
Blomberg, M., Feldt-Rasmussen, U., Andersen, K.K. and Kjaer, S.K. (2012) Thyroid Cancer in Denmark 1943-2008, before and after Iodine Supplementation. International Journal of Cancer, 131, 2360-2366.
https://doi.org/10.1002/ijc.27497
|
[9]
|
Guttman, M., Amit, I., Garber, M., French, C., Lin, M.F., Feldser, D., et al. (2009) Chromatin Signature Reveals over a Thousand Highly Conserved Large Non-Coding RNAs in Mammals. Nature, 458, 223-227.
https://doi.org/10.1038/nature07672
|
[10]
|
Gong, J., Li, Y., Liu, C.J., Xiang, Y., Li, C., Ye, Y., et al. (2017) A Pan-Cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer. Cell Reports, 21, 1968-1981.
https://doi.org/10.1016/j.celrep.2017.10.070
|
[11]
|
Rupaimoole, R., Calin, G.A., Lopez-Berestein, G. and Sood, A.K. (2016) miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discovery, 6, 235-246. https://doi.org/10.1158/2159-8290.CD-15-0893
|
[12]
|
Esteller, M. (2011) Non-Coding RNAs in Human Disease. Nature Reviews Genetics, 12, 861-874.
https://doi.org/10.1038/nrg3074
|
[13]
|
White, N.M., Zhao, S.G., Zhang, J., Rozycki, E.B., Dang, H.X., McFadden, S.D., et al. (2017) Multi-Institutional Analysis Shows That Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer. European Urology, 71, 257-266. https://doi.org/10.1016/j.eururo.2016.07.012
|
[14]
|
Wang, Y., Hu, Y., Wu, G., Yang, Y., Tang, Y., Zhang, W., et al. (2017) Long Noncoding RNA PCAT-14 Induces Proliferation and Invasion by Hepatocellular Carcinoma Cells by Inducing Methylation of miR-372. Oncotarget, 8, 34429-34441. https://doi.org/10.18632/oncotarget.16260
|
[15]
|
Song, E., Jeon, M.J., Oh, H.S., Han, M., Lee, Y.M., Kim, T.Y., et al. (2018) Do Aggressive Variants of Papillary Thyroid Carcinoma Have Worse Clinical Outcome than Classic Papillary Thyroid Carcinoma? European Journal of Endocrinology, 179, 135-142. https://doi.org/10.1530/EJE-17-0991
|
[16]
|
Jiang, C., Cheng, T., Zheng, X., Hong, S., Liu, S., Liu, J., et al. (2018) Clinical Behaviors of Rare Variants of Papillary Thyroid Carcinoma Are Associated with Survival: A Population-Level Analysis. Cancer Management and Research, 10, 465-472. https://doi.org/10.2147/CMAR.S157823
|
[17]
|
Vuong, H.G., Long, N.P., Anh, N.H., Nghi, T.D., Hieu, M.V., Hung, L.P., et al. (2018) Papillary Thyroid Carcinoma with Tall Cell Features Is as Aggressive as Tall Cell Variant: A Meta-Analysis. Endocrine Connections, 7, R286-R293.
https://doi.org/10.1530/EC-18-0333
|
[18]
|
Nixon, I.J., Simo, R., Newbold, K., Rinaldo, A., Suarez, C., Kowalski, L.P., et al. (2016) Management of Invasive Differentiated Thyroid Cancer. Thyroid, 26, 1156-1166. https://doi.org/10.1089/thy.2016.0064
|
[19]
|
Stuelten, C.H., Parent, C.A. and Montell, D.J. (2018) Cell Motility in Cancer Invasion and Metastasis: Insights from Simple Model Organisms. Nature Reviews Cancer, 18, 296-312. https://doi.org/10.1038/nrc.2018.15
|
[20]
|
Richards, E.J., Zhang, G., Li, Z.P., Permuth-Wey, J., Challa, S., Li, Y., et al. (2015) Long non-coding RNAs (LncRNA) Regulated by Transforming Growth Factor (TGF) β: LncRNA-Hit-Mediated TGFβ-Induced Epithelial to Mesenchymal Transition in Mammary Epithelia. The Journal of Biological Chemistry, 290, 6857-6867.
https://doi.org/10.1074/jbc.M114.610915
|
[21]
|
Braun, J., Hoang-Vu, C., Dralle, H. and Huttelmaier, S. (2010) Down-Regulation of MicroRNAs Directs the EMT and Invasive Potential of Anaplastic Thyroid Carcinomas. Oncogene, 29, 4237-4244. https://doi.org/10.1038/onc.2010.169
|
[22]
|
Shukla, S., Zhang, X., Niknafs, Y.S., Xiao, L., Mehra, R., Cieslik, M., et al. (2016) Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia, 18, 489-499.
https://doi.org/10.1016/j.neo.2016.07.001
|